Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04585945 · ClinicalTrials.gov registry record
COVID-19 on Placental Gene Expression and Pathology
A clinical trial, sponsored by Prisma Health-Upstate.
- Completed
- Registry status
- 68
- Enrollment target
NCT04585945: Completed study, sponsored by Prisma Health-Upstate.
NCT04585945 is a clinical trial that has completed, run by Prisma Health-Upstate. The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04585945 has completed, sponsored by Prisma Health-Upstate.
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
Study Summary
Little is known regarding the effect of antenatal COVID-19 on pregnancy outcomes. The purpose of this study is to determine of COVID-19 alters histopathology and gene expression of the placenta, as evidenced by analysis at time of delivery. The analysis will aim to identify whether resulting abnormal placental pathology or altered metabolism is associated with severity of symptoms (specifically pneumonia, or need for admission), gestational age at onset, and/or placenta efficiency. Histological and gene expression analysis of the placental post-delivery will determine if COVID-19 alters overall placental structure, vascularization, and/or the transcriptome.
Primary Outcome
Umbilical cord blood will be analyzed using an inflammatory biomarker panel (TNF, IL6, CRP, IL4, IL13)
Interventions
- DIAGNOSTIC_TEST Positive for SARS-CoV-2 infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2020-08-04 |
| Est. Completion | 2022-02-28 |
What the finished NCT04585945 record still lists
NCT04585945 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 68 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Positive for SARS-CoV-2 infection is the first listed.
NCT04585945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04585945 about?
NCT04585945 is a clinical study titled "COVID-19 on Placental Gene Expression and Pathology". Little is known regarding the effect of antenatal COVID-19 on pregnancy outcomes. The purpose of this study is to determine of COVID-19 alters histopathology and gene expression of the placenta, as evidenced by analysis at time of delivery. The analysis will aim to identify whether resulting abnorma...
What is the current status of trial NCT04585945?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2020-08-04. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT04585945?
The interventions under investigation include: Positive for SARS-CoV-2 infection (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04585945?
This trial is sponsored by Prisma Health-Upstate, which has 67 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI